GlassScriptPhysician profile
Shawn G Macalester
NPI 1871706218
$219,597.74
in general payments reported to CMS, 2019-2025
42 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $11K · 2021: $22K · 2022: $15K · 2023: $45K · 2024: $40K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $13K · Travel and Lodging: $13K · Consulting Fee: $12K · Honoraria: $11K · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,589.00 |
| Food and Beverage | $13,391.45 |
| Travel and Lodging | $12,614.89 |
| Consulting Fee | $11,952.50 |
| Honoraria | $10,550.00 |
| Education | $190.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $60,283.87 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Horizon Therapeutics Plc | $39,560.21 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $22,442.59 | 2021-2025 | Saphnelo |
| Amgen INC. | $18,829.59 | 2019-2025 | Tavneos, Otezla, Krystexxa |
| Celgene Corporation | $17,078.81 | 2019-2024 | Orencia |
| Regeneron Healthcare Solutions, INC. | $12,249.18 | 2019 | |
| Genzyme Corporation | $10,434.89 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $9,308.52 | 2019-2025 | Cosentyx |
| Abbvie INC. | $8,670.74 | 2019-2025 | |
| Pfizer INC. | $7,640.69 | 2019-2025 | |
| Lilly USA, LLC | $5,423.47 | 2019-2025 | Taltz, Zepbound, Omvoh |
| Sobi, INC | $1,563.23 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,479.23 | 2019-2023 | Stelara, Simponi Aria, Tremfya |
| Ucb, INC. | $977.23 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $539.78 | 2019-2025 | Benlysta |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $467.47 | 2019-2025 | Actemra, Gazyva, Rituxan |
| E.R. Squibb & Sons, L.L.C. | $461.94 | 2019-2025 | Orencia |
| Organon LLC | $307.46 | 2022-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $302.87 | 2019-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $281.82 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $281.20 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $213.71 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.59 | 2021-2023 | Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $102.62 | 2023-2025 | Idacio |
| Actelion Pharmaceuticals US, INC. | $66.67 | 2023-2025 | Opsumit, Uptravi |
| Radius Health, INC. | $63.16 | 2024-2025 | Tymlos |
| Gilead Sciences, INC. | $57.98 | 2020-2023 | |
| Sandoz INC. | $55.88 | 2023-2025 | Hyrimoz, Jubbonti |
| Invivyd INC | $34.61 | 2024-2025 | Pemgarda |
| Madrigal Pharmaceuticals | $31.09 | 2024 | Resmetirom |
| Mallinckrodt Enterprises LLC | $30.62 | 2019 | |
| Arcutis Biotherapeutics, INC. | $24.23 | 2025 | Zoryve |
| Kyowa Kirin, INC. | $24.09 | 2023 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $24.09 | 2023 | Truxima |
| Ultragenyx Pharmaceutical INC. | $22.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.00 | 2019 | |
| Antares Pharma, INC. | $19.45 | 2019 | |
| Shorla Oncology INC. | $17.87 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.77 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $16.60 | 2019 | |
| Merck Sharp & Dohme LLC | $13.70 | 2019 | |
| Pacira Therapeutics, INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Macalester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.